View More Recent Stories
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
Piper Sandler Sees an 'Attractive Risk/Reward' on Abivax (ABVX) Shares
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
Abivax (ABVX) Appoints Dominik Höchli to its Board
-
Guggenheim Reiterates Buy Rating on Abivax (ABVX), PT $50
-
BTIG Reiterates Buy Rating on Abivax (ABVX)
-
Morgan Stanley Assumes Abivax (ABVX) at Equalweight
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
JMP Securities Biotechnology Overview
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
Abivax (ABVX) Announces Board Changes
-
Piper Sandler Reiterates Overweight Rating on Abivax (ABVX) Following New IBD Surveys
-
JMP Securities Starts Abivax (ABVX) at Market Outperform
-
Abivax (ABVX) Announces $150M ATM Program
-
Abivax (ABVX) Appoints Mark Stenhouse as Board Observer
-
Abivax (ABVX) Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod
-
Guggenheim Reiterates Buy Rating on Abivax (ABVX)
-
Piper Sandler Reiterates Overweight Rating on Abivax (ABVX)
-
BTIG Reiterates Buy Rating on Abivax (ABVX)
-
Abivax (ABVX) Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod
-
Piper Sandler Reiterates Overweight Rating on Abbvie (ABBV)
-
Piper Sandler Reiterates Overweight Rating on Abivax (ABVX)
-
Piper Sandler Reiterates Overweight Rating on Abivax (ABVX)
-
Abivax (ABVX) Provides Operational and Key Program Update

